Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response

A. Sultan*, J. Wormann, J. Luker, J.H. van der Bruck, T. Plenge, V. Rudolph, A. Klinke, J. Heijman, M. Mollenhauer, T. Ravekes, S. Baldus, D. Steven

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objectives This study aimed to determine if changes in myeloperoxidase (MPO) levels correlate with response to cardiac resynchronization therapy (CRT) and the potential role of MPO as a predictor of response to CRT. Background CRT is a well-established treatment option in chronic heart failure (CHF) with 50-80% of patients benefiting. Inflammation and oxidative stress play a key role in CHF pathophysiology. Previous studies have demonstrated increased levels of MPO in CHF patients, but the correlation with CRT response remains incompletely understood. Methods Fifty-three patients underwent CRT implantation. During follow-up, patients were divided into two groups, responders and non-responders to CRT, based on improved physical capacity and NYHA classification. Levels of MPO and NT-pro-brain-natriuretic-peptide (NT-proBNP) were determined prior to implantation, 30 and 90 days after. Physical capacity, including a 6-min walking-test, NYHA class, and LVEF were evaluated at baseline and during follow-up. Results Thirty-four patients (64%) responded to CRT, showing improved physical capacity and LVEF. All responders revealed a significant decrease of MPO levels (503.8 ng/ml vs. 188.4 ng/ml;p < 0.001). Non-responding patients did not show any significant changes in clinical parameters or MPO levels (119.6 ng/ml vs. 134.3 ng/ml;p = 0.672) during follow-up. At baseline, physical capacity and NYHA class, as well as MPO levels differed significantly between both groups (p < 0.001). A ROC analysis identified an MPO cut-off value for response to CRT of 242 ng/ml with a sensitivity of 93.5% and specificity of 71.4%. There was a strong correlation between MPO and improvement of LVEF (Spearman's rho: - 0.453;p = 0.005) and physical capacity (Spearman's rho: - 0.335;p = 0.042). Conclusions Response to CRT and course of MPO levels correlate significantly. MPO levels differ between responders and non-responders prior to CRT, which may indicate an additional value of MPO as a predictor for CRT response. Further randomized studies are required to confirm our data in larger patient cohorts.

Original languageEnglish
Pages (from-to)1173-1180
Number of pages8
JournalClinical research in cardiology
Issue number8
Early online date20 Jun 2020
Publication statusPublished - Aug 2021


  • brain natriuretic peptide
  • cardiac resynchronization therapy
  • inflammation
  • myeloperoxidase
  • non-response
  • response
  • Inflammation
  • Cardiac resynchronization therapy
  • Response
  • Non-response
  • Myeloperoxidase

Cite this